References
Eliopoulos GM, Klimm K, Eliopoulos CT, et al. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother 1993; 37: 366–70
Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP 99,219 combined with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother 1994; 38: 2471–6
Child J, Andrews J, Boswell F, et al. The in-vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother 1995; 35: 869–76
Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 1995; 35: 230–2
Visalli MA, Bajaksouzian S, Jacobs MR, et al. Comparative activity of trovafloxacin alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrob Agents Chemother 1997; 41: 1475–81
Bajaksouzian S, Visalli MA, Jacobs MR, et al. Activities of levofloxacin, ofloxacin and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies. Antimicrob Agents Chemother 1997; 41: 1073–6
Eliopoulos GM, Moellering Jr RC. Antimicrobial combinations. In: Lorian VA, editor. Antibiotics in laboratory medicine. Baltimore: Williams and Wilkins, 1996; 330–96
Teng R, Harris SC, Nix DE, et al. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother 1995; 36: 385–94
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Visalli, M.A., Bajaksouzian, S., Jacobs, M.R. et al. Synergistic Activity of Trovafloxacin with Other Agents. Drugs 58 (Suppl 2), 141–143 (1999). https://doi.org/10.2165/00003495-199958002-00036
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199958002-00036